バージニアにおける肺がんの臨床試験
バージニア内の拠点で、肺がんに関する58件の研究が参加者を募集しています。
バージニア内の都市
- Arlington41件の研究
- Richmond14件の研究
- Charlottesville13件の研究
- Alexandria7件の研究
- Winchester4件の研究
- Lynchburg3件の研究
- Norfolk3件の研究
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Ballad Health Cancer Care - Bristol, Bristol
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- 他7件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Virginia Cancer Specialists (VCS) ( Site 0408), Fairfax
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06780098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
- 他1件
被験者募集中第3相
70歳以上 · 全性別 · 2026/10/01更新 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- University of Virginia Cancer Center, Charlottesville
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT04181060Empathic Communication Skills (ECS) Training
- Chesapeake Regional Healthcare (Data Collection Only), Chesapeake
被験者募集中健康なボランティア歓迎
18歳〜100歳 · 全性別 · 2026/10/01更新 · NCT05456841Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- Virginia Cancer Institute, Richmond
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Virginia Cancer Specialists, Fairfax
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Virginia Cancer Specialists, Fairfax
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Inova Schar Cancer Infusion Pharmacy, Fairfax
- Inova Schar Cancer, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07519655Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Virginia Commonwealth University, Richmond
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07063745Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Fairfax
被験者募集中第2相
18歳〜95歳 · 全性別 · 2026/09/23更新 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax
- VCU Massey Cancer Center, Richmond
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University of Virginia Health System, Charlottesville
- Virginia Commonwealth University (Vcu), Richmond
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07100080A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Next Oncology Virginia Cancer Specialist, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NEXT - Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07349537Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06287775BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Virginia Cancer Specialists, Fairfax
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07625644Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NEXT Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Virginia Oncology Associates, Norfolk
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of Virginia Health System, Charlottesville
- USO - Virginia Cancer Specialists, Fairfax
- VCU Health Adult Outpatient Pavillion, Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- USO-Virginia Cancer Specialists, PC, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06561685Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
- University of Virginia Cancer Center, Charlottesville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07012031AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Fairfax
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/09/04更新 · NCT07038343Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- NEXT Oncology, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06343402The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- 他5件
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Shenandoah Oncology, P.C., Winchester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT07185997Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Virginia Cancer Specialists, Fairfax
- Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg
- Virginia Commonwealth University School of Medicine, Richmond
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT06712355Health Education Approach to Lung Screening
- Virginia Commonwealth University, Richmond
被験者募集中健康なボランティア歓迎
50歳〜80歳 · 全性別 · 2026/08/25更新 · NCT06070870Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Inova Alexandria Hospital, Alexandria
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06500481Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- NEXT Oncology - Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT07444814A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NEXT Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT05652686Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/09更新 · NCT07315113Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- NEXT Oncology Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/30更新 · NCT06162221A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/29更新 · NCT07458347ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。